Trial of nelipepimut S (NeuVax) in patients with gastric cancer in India
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
Price : $35 *
At a glance
- Drugs Nelipepimut-S (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 29 Dec 2017 According to a Sellas Life Sciences Group media release, SELLAS Life Science Group acquired Galena Biopharma, and subsequently Galena Biopharma changed its name to SELLAS Life Science Group.
- 22 Jan 2014 New trial record
- 14 Jan 2014 Galena Biopharma and Dr. Reddy's Laboratories have formed a strategic partnership for the development of nelipepimut S in India, according to a media release.